5.4.2006: Meldung: Report from Gambro"s Annual General Meeting
The Meeting approved the proposed dividend to shareholders of SEK 1.30 per share. The record date was determined as Friday, April 7, 2006. The dividend is scheduled to be distributed by VPC AB (the Swedish Securities Register Center) on Wednesday, April 12, 2006.
The Meeting approved a total fee to the Board of Directors for 2006 of SEK 4,300,000 for distribution among those members elected by the Annual General Meeting who are not employees of the Company.
The Meeting approved the decision by the Board of Directors regarding the size of and the main principles for Gambro"s employee stock option program for 2006 as well as for two share programs for 2006, i.e. restricted shares and performance shares.
The Meeting decided that a Nomination Committee is to be established composed of representatives of the four largest shareholders in terms of votes plus the Chairman of the Board. The composition of the Nomination Committee shall be announced six months before the Annual General Meeting 2007. The task of the Nomination Committee will be to submit proposals to the Annual General Meeting 2007 regarding the Chairman of the Annual General Meeting, the composition of the Board of Directors, the Chairman of the Board, the Board"s fee, auditors and the auditors" fee. The names of the four representatives shall be announced immediately after their appointment.
Claes Dahlbäck (Chairman), Wilbur H Gantz, Håkan Mogren and Lena Treschow Torell were elected by the Board to serve on the Compensation Committee.
Peter H Grassman (Chairman), Claes Dahlbäck, Adine Grate Axén and Håkan Mogren were elected by the Board to serve on the Audit Committee.
For further information please contact:
Paula Treutiger, Vice President, Corporate Communications, tel. +46-8-613 65 99, +46-73-366 65 99
Fredrik Dalborg, Director, Investor Relations, Corporate Finance, tel. +46-8-613 65 84, +46-73-366 65 84
Gambro is a global medical technology company with related services and has leading positions in renal care - services and products – and blood component technology. Gambro Renal Products develops and supplies hemodialysis, peritoneal dialysis, and acute renal and liver dialysis products, therapies and services. Gambro Healthcare is a provider of end-stage renal disease treatment and patient care. Gambro BCT develops and provides blood collection, apheresis and cell therapy products and services.